Stock Co Pharmstandard Joint Form 4 ARGOS THERAPEUTICS / Joint Stock Co Pharmstandard Public ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pharmstandard International S.A.

(Last) (First) (Middle)

10A, RUE HENRY SCHNADT

(Street)

LUXEMBOURG N4 L-2530

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARGOS THERAPEUTICS INC [ ARGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2017

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Secured Promissory Note	$0.5	06/21/2017		P(1)		$6,000,000		06/21/2017	06/21/2022	Common Stock	12,000,000	(1)	$6,000,000	I	See footnote(2)

1. Name and Address of Reporting Person^*

Pharmstandard International S.A.

(Last) (First) (Middle)

10A, RUE HENRY SCHNADT

(Street)

LUXEMBOURG N4 L-2530

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Public Joint Stock Co Pharmstandard

(Last) (First) (Middle)

LIKHACEVSKY DRIVE 5 "B"

(Street)

DOLGOPRUDNY 1Z 141700

(City) (State) (Zip)

Explanation of Responses:

1. This Convertible Secured Promissory Note (the "Note") was issued by the Issuer in principal amount of $6,000,000 for a purchase price of $6,000,000, and bears interest at a rate of 9.5% per annum. The Reporting Person may at any time and from time to time convert all outstanding principal and any accrued but unpaid interest under the Note into shares of the Issuer's common stock at a price per share equal to $0.50, subject to adjustment as provided in the Note.

2. Pharmstandard International S.A. is a wholly owned subsidiary of Pharmstandard JSC. As the parent entity, Pharmstandard JSC has voting power over the shares of the Issuer held by Pharmstandard International S.A.

Remarks:

	/s/ Eriks Martinovskis, Director, Pharmstandard International S.A.	06/23/2017
	/s/ Victor Fedlyuk, Deputy General Director for Legal Affairs, Pharmstandard JSC	06/23/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.